Literature DB >> 17869669

Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.

Kevin O Hicks1, Hilary Myint, Adam V Patterson, Frederik B Pruijn, Bronwyn G Siim, Kashyap Patel, William R Wilson.   

Abstract

PURPOSE: To compare oxygen dependence and tissue transport properties of a new hypoxia-activated prodrug, PR-104A, with tirapazamine, and to evaluate the implications for antitumor activity when combined with radiotherapy. METHODS AND MATERIALS: Oxygen dependence of cytotoxicity was measured by clonogenic assay in SiHa cell suspensions. Tissue transport parameters were determined using SiHa multicellular layers. Spatially resolved pharmacokinetic (PK) and pharmacodynamic (PD) models were developed to predict cell killing in SiHa tumors and tested by clonogenic assay 18 h after treatment with the corresponding phosphate ester, PR-104.
RESULTS: The K-value (oxygen concentration to halve cytotoxic potency) of PR-104A was 0.126 +/- 0.021 microM (10-fold lower than tirapazamine at 1.30 +/- 0.28 microM). The diffusion coefficient of PR-104A in multicellular layers (4.42 +/- 0.15 x 10(-7) cm2 s(-1)) was lower than that of tirapazamine (1.30 +/- 0.05 x 10(-6) cm2 s(-1)) but PK modeling predicted better penetration to hypoxic cells in tumors because of its slower metabolism. The tirapazamine PK/PD model successfully predicted the measured activity in combination with single-dose radiation against SiHa tumors, and the PR-104A model underpredicted the activity, which was greater for PR-104 than for tirapazamine (at equivalent host toxicity) both with radiation and as a single agent.
CONCLUSION: PR-104/PR-104A has different PK/PD properties from tirapazamine and superior activity with single-dose radiotherapy against SiHa xenografts. We have inferred that PR-104A is better able to kill cells at intermediate partial pressure of oxygen in tumors than implied by the PK/PD model, most likely because of a bystander effect resulting from diffusion of its activated metabolites from severely hypoxic zones.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17869669     DOI: 10.1016/j.ijrobp.2007.05.049

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  22 in total

1.  Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins.

Authors:  Michael P Hay; Kevin O Hicks; Karin Pchalek; Ho H Lee; Adrian Blaser; Frederik B Pruijn; Robert F Anderson; Sujata S Shinde; William R Wilson; William A Denny
Journal:  J Med Chem       Date:  2008-10-11       Impact factor: 7.446

2.  Six degrees of separation: the oxygen effect in the development of radiosensitizers.

Authors:  Bryan T Oronsky; Susan J Knox; Jan Scicinski
Journal:  Transl Oncol       Date:  2011-08-01       Impact factor: 4.243

3.  Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia.

Authors:  Blake A Winn; Zhe Shi; Graham J Carlson; Yifan Wang; Benson L Nguyen; Evan M Kelly; R David Ross; Ernest Hamel; David J Chaplin; Mary L Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem Lett       Date:  2016-12-01       Impact factor: 2.823

4.  Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.

Authors:  Peter J Houghton; Richard Lock; Hernan Carol; Christopher L Morton; Doris Phelps; Richard Gorlick; E Anders Kolb; Stephen T Keir; C Patrick Reynolds; Min H Kang; John M Maris; Amy W Wozniak; Yongchuan Gu; William R Wilson; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2010-12-27       Impact factor: 3.167

5.  Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.

Authors:  Kevin O Hicks; Bronwyn G Siim; Jagdish K Jaiswal; Frederik B Pruijn; Annie M Fraser; Rita Patel; Alison Hogg; H D Sarath Liyanage; Mary Jo Dorie; J Martin Brown; William A Denny; Michael P Hay; William R Wilson
Journal:  Clin Cancer Res       Date:  2010-08-20       Impact factor: 12.531

Review 6.  Targeting hypoxia in cancer therapy.

Authors:  William R Wilson; Michael P Hay
Journal:  Nat Rev Cancer       Date:  2011-06       Impact factor: 60.716

7.  Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.

Authors:  Maria R Abbattista; Stephen M F Jamieson; Yongchuan Gu; Jennifer E Nickel; Susan M Pullen; Adam V Patterson; William R Wilson; Christopher P Guise
Journal:  Cancer Biol Ther       Date:  2015-04-14       Impact factor: 4.742

8.  Effectiveness of combined modality radiotherapy of orthotopic human squamous cell carcinomas in Nu/Nu mice using cetuximab, tirapazamine and MnSOD-plasmid liposome gene therapy.

Authors:  Michael W Epperly; Stephen Y Lai; Anthony J Kanai; Neal Mason; Brian Lopresi; Tracey Dixon; Darcy Franicola; Yunyun Niu; William R Wilson; Joel S Greenberger
Journal:  In Vivo       Date:  2010 Jan-Feb       Impact factor: 2.155

9.  Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.

Authors:  Cho Rong Hong; Sunali Y Mehta; H D Sarath Liyanage; Sarah P McManaway; Ho H Lee; Jagdish K Jaiswal; Gib Bogle; Moana Tercel; Frederik B Pruijn; William R Wilson; Kevin O Hicks
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-10       Impact factor: 3.333

Review 10.  Therapeutic targeting of the hypoxic tumour microenvironment.

Authors:  Dean C Singleton; Andrew Macann; William R Wilson
Journal:  Nat Rev Clin Oncol       Date:  2021-07-29       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.